Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can cause acute respiratory distress syndrome, hypercoagulability, hypertension, and multiorgan dysfunction. Effective antivirals with safe clinical profile are urgently needed to improve the overall prognosis. In an analysis of a randomly collected cohort of 124 patients with COVID-19, we found that hypercoagulability as indicated by elevated concentrations of D-dimers was associated with disease severity. By virtual screening of a U.S. FDA approved drug library, we identified an anticoagulation agent dipyridamole (DIP) in silico, which suppressed SARS-CoV-2 replication in vitro. In a proof-of-concept trial involving 31 patients with COVID-19, DIP supplementation was associated with significantly decreased concentrations of D-dimers (P < 0.05), increased lymphocyte and platelet recovery in the circulation, and markedly improved clinical outcomes in comparison to the control patients. In particular, all 8 of the DIP-treated severely ill patients showed remarkable improvement: 7 patients (87.5%) achieved clinical cure and were discharged from the hospitals while the remaining 1 patient (12.5%) was in clinical remission.

严重的急性呼吸综合征冠状病毒2（SARS-CoV-2）感染可导致急性呼吸窘迫综合征，高凝性，高血压和多器官功能障碍。迫切需要具有安全临床资料的有效抗病毒药物，以改善总体预后。在对124例COVID-19患者的随机收集队列的分析中，我们发现D-二聚体浓度升高表明高凝状态与疾病严重程度相关。通过对美国FDA批准的药物库进行虚拟筛选，我们在计算机上鉴定了抗凝剂潘生丁（DIP），该药物可在体外抑制SARS-CoV-2复制。在一项涉及31名COVID-19患者的概念验证试验中，DIP的补充与D-二聚体的浓度显着降低（P  <0.05），循环中淋巴细胞和血小板恢复的增加以及临床效果显着改善相关。给对照患者。尤其是，所有接受DIP治疗的8名重症患者均表现出显着改善：7名患者（87.5％）取得了临床治愈，已出院，其余1名患者（12.5％）处于临床缓解期。